BRPI0911228A2 - compostos e composições como inibidores de proteínas quinase - Google Patents
compostos e composições como inibidores de proteínas quinaseInfo
- Publication number
- BRPI0911228A2 BRPI0911228A2 BRPI0911228A BRPI0911228A BRPI0911228A2 BR PI0911228 A2 BRPI0911228 A2 BR PI0911228A2 BR PI0911228 A BRPI0911228 A BR PI0911228A BR PI0911228 A BRPI0911228 A BR PI0911228A BR PI0911228 A2 BRPI0911228 A2 BR PI0911228A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- compounds
- protein kinase
- kinase inhibitors
- inhibitors
- Prior art date
Links
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4311108P | 2008-04-07 | 2008-04-07 | |
| US11602308P | 2008-11-19 | 2008-11-19 | |
| PCT/US2009/039383 WO2009126515A1 (en) | 2008-04-07 | 2009-04-03 | Compounds and compositions as protein kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0911228A2 true BRPI0911228A2 (pt) | 2017-05-30 |
Family
ID=40756678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0911228A BRPI0911228A2 (pt) | 2008-04-07 | 2009-04-03 | compostos e composições como inibidores de proteínas quinase |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8592432B2 (pt) |
| EP (1) | EP2271630B1 (pt) |
| JP (1) | JP5298187B2 (pt) |
| KR (1) | KR101238585B1 (pt) |
| CN (1) | CN102131788B (pt) |
| AU (1) | AU2009233964B2 (pt) |
| BR (1) | BRPI0911228A2 (pt) |
| CA (1) | CA2720946C (pt) |
| EA (1) | EA018282B1 (pt) |
| ES (1) | ES2570127T3 (pt) |
| MX (1) | MX2010010968A (pt) |
| WO (1) | WO2009126515A1 (pt) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI389893B (zh) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二（芳胺基）芳基化合物 |
| JP2011523646A (ja) | 2008-05-21 | 2011-08-18 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのリン誘導体 |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| JP5263304B2 (ja) * | 2009-02-06 | 2013-08-14 | 日本新薬株式会社 | アミノピラジン誘導体及び医薬 |
| MX2011011875A (es) | 2009-05-08 | 2011-12-08 | Astellas Pharma Inc | Compuesto de carboxamida heterociclica diamino. |
| ES2622138T3 (es) * | 2010-06-23 | 2017-07-05 | Hanmi Science Co., Ltd. | Nuevos derivados de pirimidina condensados para la inhibición de la actividad tirosina quinasa |
| WO2012005299A1 (ja) * | 2010-07-07 | 2012-01-12 | 日本新薬株式会社 | Ｒｏｓチロシンキナーゼ阻害剤 |
| RU2013120966A (ru) * | 2010-10-08 | 2014-11-20 | Эббви Инк. | ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ |
| KR20130139999A (ko) * | 2010-10-14 | 2013-12-23 | 어리어드 파마슈티칼스, 인코포레이티드 | Egfr-유도된 암의 세포 증식을 억제하는 방법 |
| PL2651918T3 (pl) * | 2010-12-17 | 2017-12-29 | Novartis Ag | Krystaliczne formy 5-chloro-N2-(2-izopropoksy-5-metylo-4-piperydyn-4-ylofenylo)-N4-[2-(propano-2-sulfonylo)-fenylo]-pirymidyno-2,4-diaminy |
| US8362023B2 (en) | 2011-01-19 | 2013-01-29 | Hoffmann-La Roche Inc. | Pyrazolo pyrimidines |
| PT2670401E (pt) * | 2011-02-02 | 2015-10-12 | Novartis Ag | Métodos de utilização de inibidores de alk |
| CN102757390B (zh) * | 2011-04-27 | 2015-04-22 | 中国中化股份有限公司 | 一种制备2-甲氧基-4-肼基-5-氟嘧啶的方法 |
| AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| KR101379808B1 (ko) | 2012-04-03 | 2014-04-24 | 울산대학교 산학협력단 | 산화질소 생성 억제용 피라졸로피리미딘 유도체 화합물 |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| CN104854101B (zh) | 2012-11-06 | 2018-05-01 | 上海复尚慧创医药研究有限公司 | Alk激酶抑制剂 |
| CN102977104A (zh) * | 2012-11-26 | 2013-03-20 | 盛世泰科生物医药技术(苏州)有限公司 | 2,4-二氯-7-氢-吡咯并（2,3）嘧啶的合成 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| CN104109149B (zh) * | 2013-04-22 | 2018-09-28 | 苏州泽璟生物制药有限公司 | 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物 |
| CN104672214B (zh) * | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | 具有alk抑制活性的化合物及其制备与用途 |
| AU2014372166B2 (en) * | 2013-12-23 | 2017-10-26 | Novartis Ag | Pharmaceutical combinations |
| EP3129376B1 (en) | 2014-03-27 | 2018-12-26 | Janssen Pharmaceutica NV | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4h-pyrazolo[1,5-a][1,4]diazepine derivatives as ros1 inhibitors |
| US10053458B2 (en) | 2014-06-17 | 2018-08-21 | Korea Research Institute Of Chemical Technology | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient |
| CN105524045B (zh) * | 2014-10-22 | 2020-04-10 | 山东轩竹医药科技有限公司 | 四环类间变性淋巴瘤激酶抑制剂 |
| CN104803908A (zh) * | 2015-03-26 | 2015-07-29 | 药源药物化学（上海）有限公司 | 2-异丙氧基-5-甲基-4-(4-哌啶基)苯胺二盐酸盐的水合物、其制备方法及用途 |
| CN106188060A (zh) * | 2015-04-29 | 2016-12-07 | 厦门大学 | 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用 |
| CN106699810A (zh) * | 2015-11-17 | 2017-05-24 | 清华大学 | 一种含氮杂环化合物及其制备方法与在抑制激酶活性中的应用 |
| CN107216319B (zh) * | 2016-03-21 | 2021-10-08 | 中国科学院上海药物研究所 | 一种2，4-二氨基嘧啶类衍生物、其制备方法及用途 |
| KR101937529B1 (ko) * | 2016-07-26 | 2019-01-14 | 한국화학연구원 | 신규한 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| SG11201901251SA (en) | 2016-08-29 | 2019-03-28 | Univ Michigan Regents | Aminopyrimidines as alk inhibitors |
| CN107793417B (zh) * | 2016-09-05 | 2020-06-09 | 复旦大学 | 吡咯并[2,3-d]嘧啶类化合物及其盐，及制备方法和药用用途 |
| KR102477063B1 (ko) * | 2016-10-28 | 2022-12-12 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물 |
| CN108276410B (zh) * | 2017-01-06 | 2021-12-10 | 首药控股(北京)股份有限公司 | 一种间变性淋巴瘤激酶抑制剂及其制备方法和用途 |
| KR102032418B1 (ko) * | 2017-06-15 | 2019-10-16 | 한국화학연구원 | 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
| US20190338244A1 (en) * | 2017-11-30 | 2019-11-07 | New York Medical College | Multipotent adult stem cells: characterization and use |
| CN112645929B (zh) * | 2019-10-11 | 2022-03-11 | 苏州泽璟生物制药股份有限公司 | 异丙磺酰基苯基嘧啶类化合物或其盐的多晶型物 |
| CN114430741A (zh) * | 2019-10-17 | 2022-05-03 | 贝达药业股份有限公司 | Egfr抑制剂、组合物及其制备方法 |
| CN111484484B (zh) * | 2020-04-13 | 2021-11-23 | 沈阳药科大学 | 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用 |
| JP7807025B2 (ja) * | 2021-12-30 | 2026-01-27 | コリア リサーチ インスティチュート オブ ケミカル テクノロジー | ピラゾロピリミジン誘導体及びこれを有効成分として含有する抗癌用薬学的組成物 |
| KR102847312B1 (ko) * | 2021-12-30 | 2025-08-19 | 한국화학연구원 | 피라졸로피리미딘 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
| CN114805301B (zh) * | 2022-04-29 | 2024-04-05 | 沈阳药科大学 | 2,4-二芳氨基嘧啶类化合物及其制备方法和应用 |
| CN116284001B (zh) * | 2023-01-30 | 2025-06-06 | 中国药科大学 | Dclk1抑制剂、制备方法、药物组合物和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1066147C (zh) * | 1995-11-01 | 2001-05-23 | 诺瓦提斯公司 | 嘌呤衍生物及其制备方法 |
| UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| ES2421139T3 (es) * | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
| DK1663242T3 (da) * | 2003-08-07 | 2011-08-01 | Rigel Pharmaceuticals Inc | 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler |
| ATE542801T1 (de) * | 2003-08-15 | 2012-02-15 | Novartis Ag | Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine |
| EP1758887A1 (en) | 2004-05-14 | 2007-03-07 | Pfizer Products Incorporated | Pyrimidine derivatives for the treatment of abnormal cell growth |
| EP1598343A1 (de) * | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
| GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| RU2007123675A (ru) | 2004-11-24 | 2008-12-27 | Новартис АГ (CH) | Комбинации ингибиторов jak |
| JP2008013527A (ja) * | 2006-07-10 | 2008-01-24 | Sankyo Co Ltd | チエノ［３，２−ｄ］ピリミジン−２，４−ジアミン誘導体 |
| US8314234B2 (en) * | 2006-09-25 | 2012-11-20 | Janssen Pharmaceutica N.V. | Bicyclic pyrimidine kinase inhibitors |
| MX2009004426A (es) | 2006-10-23 | 2009-08-12 | Cephalon Inc | Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met. |
| EA019941B1 (ru) | 2006-12-08 | 2014-07-30 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве ингибиторов протеинкиназы |
| JP5208123B2 (ja) | 2006-12-08 | 2013-06-12 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| BRPI0815979A2 (pt) | 2007-08-28 | 2017-06-13 | Irm Llc | compostos e composições com inibidores de quinase, bem como uso dos mesmos |
| WO2009032703A1 (en) | 2007-08-28 | 2009-03-12 | Irm Llc | 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors |
-
2009
- 2009-04-03 AU AU2009233964A patent/AU2009233964B2/en not_active Ceased
- 2009-04-03 JP JP2011504086A patent/JP5298187B2/ja not_active Expired - Fee Related
- 2009-04-03 WO PCT/US2009/039383 patent/WO2009126515A1/en not_active Ceased
- 2009-04-03 CN CN200980121030.5A patent/CN102131788B/zh not_active Expired - Fee Related
- 2009-04-03 ES ES09730392T patent/ES2570127T3/es active Active
- 2009-04-03 EP EP09730392.9A patent/EP2271630B1/en not_active Not-in-force
- 2009-04-03 BR BRPI0911228A patent/BRPI0911228A2/pt not_active IP Right Cessation
- 2009-04-03 US US12/936,199 patent/US8592432B2/en not_active Expired - Fee Related
- 2009-04-03 CA CA2720946A patent/CA2720946C/en not_active Expired - Fee Related
- 2009-04-03 EA EA201001597A patent/EA018282B1/ru not_active IP Right Cessation
- 2009-04-03 MX MX2010010968A patent/MX2010010968A/es active IP Right Grant
- 2009-04-03 KR KR1020107024933A patent/KR101238585B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2271630A1 (en) | 2011-01-12 |
| EA201001597A1 (ru) | 2011-06-30 |
| WO2009126515A8 (en) | 2010-10-21 |
| WO2009126515A1 (en) | 2009-10-15 |
| EA018282B1 (ru) | 2013-06-28 |
| KR101238585B1 (ko) | 2013-02-28 |
| CN102131788B (zh) | 2014-03-19 |
| KR20110015414A (ko) | 2011-02-15 |
| JP5298187B2 (ja) | 2013-09-25 |
| JP2011516555A (ja) | 2011-05-26 |
| EP2271630B1 (en) | 2016-03-23 |
| MX2010010968A (es) | 2010-10-26 |
| CA2720946C (en) | 2013-05-28 |
| US8592432B2 (en) | 2013-11-26 |
| US20110135668A1 (en) | 2011-06-09 |
| CA2720946A1 (en) | 2009-10-15 |
| AU2009233964B2 (en) | 2012-06-07 |
| CN102131788A (zh) | 2011-07-20 |
| ES2570127T3 (es) | 2016-05-17 |
| AU2009233964A1 (en) | 2009-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2019014I2 (el) | Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης | |
| BRPI0914652A2 (pt) | compostos e composições como inibidores de quinase | |
| CY2019009I2 (el) | Αναστολεις πρωτεϊνικων κινασων | |
| BRPI0719797A2 (pt) | compostos e composições como inibidores de proteína cinase | |
| BRPI0912668A2 (pt) | composto e composições como inibidores de quinase | |
| BR112012004448A2 (pt) | "compostos e composições como inibidores de proteína cinase" | |
| BRPI0906973A2 (pt) | Compostos e composições como inibidores de cinase. | |
| BRPI0910668A2 (pt) | inibidores de proteína quinases | |
| BRPI0908849A2 (pt) | Composto e composições como c-kit e inibidores de pdgfr quinase | |
| BRPI0811516A2 (pt) | Compostos e composições como inibidores de c-kit e pdgfr cinase | |
| BRPI0910979A2 (pt) | compostos e composições como inibidores de quinase | |
| BRPI0920135A2 (pt) | imidazopiridazinacarbonitrilos úteis como inibidores de quinase | |
| BRPI0913879A2 (pt) | fenilpirazinonas como inibidores de quinase | |
| BRPI0914545A2 (pt) | compostos e composições como inibidores de quinase | |
| BRPI0716477A2 (pt) | Derivados heteroarila como inibidores de quinase protéica | |
| BRPI0920239A2 (pt) | compostos heterocíclicos como inibidores de proteínas quinases | |
| BRPI0912475A2 (pt) | compostos como inibidores de quinase | |
| BRPI0811517A2 (pt) | Compostos e composições como inibidores de c-kit e pdgfr cinase. | |
| BRPI0810374A2 (pt) | Inibidores específicos do pdgfrbeta | |
| BRPI0914936A2 (pt) | naftiridininonas como inibidores de aurora quinase | |
| BRPI0910691A2 (pt) | compostos e composições como inibidores de itpkb | |
| BRPI0716198A2 (pt) | Pirrolo-isoquinolinas como inibidores de cinase | |
| LTC2379528I2 (lt) | Baltymų kinazės slopikliai | |
| BRPI0907574A2 (pt) | Inibidores de ligação de proteína quinase | |
| DOP2009000099A (es) | Compuestos y composiciones como inhibidores de proteina cinasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |